Aim/Background: Though sorafenib has been used against advanced hepatocellular carcinoma with major portal vein tumor thrombosis (HCC-PVTT), the prognosis has not been improved enough. We compared the prognoses of HCC-PVTT after treatment with sorafenib or transcatheter-arterial chemo-infusion with cisplatin (TAI). Method/Patients: Clinical findings for 34 HCC-PVTT patients and without extra-hepatic metastasis, who were treated with sorafenib (n=8) or TAI (n=26), were retrospectively evaluated. Results: Hepatic reserve function was better in the sorafenib-group (Child-Pugh A : B : C ; 8 : 0 : 0 vs. 12 : 10 : 4, P=0.022), whereas the 6-month and 1-year survival rates in the TAI-group were better (52.5%, 31.5% vs. 16.7%, 0%; P=0.004). Conclusion: TAI is thought to be more effective than sorafenib, though establishment of an effective regimen and additional evidence of the efficacy of transcatheter chemo-infusion therapy are needed.
